Skip to content
Back to Investors
V

Ventura

Venture Capital

Ventura Capital invests in consumer technology disruptors.

Portfolio

9

companies

Investment by month

By category

  • Uncategorised£400M
  • FinTech£277M
  • Hardware£43.6M
  • InsurTech£28.2M
  • HealthTech£22.0M

By location

  • Portugal£400M
  • London£335M
  • Cambridge£22.0M
  • New York£14.4M

Portfolio companies

A

Allica

Allica provides specialised business banking and lending services for established small and medium-sized enterprises.

D

DnaNudge

DnaNudge provides consumer genetics testing and rapid medical diagnostics.

I

Invstr

Invstr operates a social investment application providing retail traders with educational tools and brokerage services.

Owlstone Medical

Owlstone Medical

Owlstone Medical creates breath biopsy technology for non-invasive disease detection.

Plum

Plum

Plum provides a smart money application that helps users automate savings and investments.

Railsbank

Railsbank

Railsbank provides an embedded finance platform that lets companies build custom financial products.

View all 9 companies

Team

ME

Mo El Husseiny

Managing Partner

Mo brings investment and acquisitions experience from Goldman Sachs, Mubadala, and Ventura Capital. He also serves as vice chairman of Royal Albert Hall America.

LinkedIn

Recent investments

Series D+
$155M

Ventura Capital, GLG, and Sona AM led the financing round to support international growth and technology investments.

"Allica is a world-class business that is executing exceptionally well in a large, underserved market. Ventura is proud to be a major investor in Allica’s Series D, and we are ready to support this exceptional team’s next stage of growth into international markets."
— Mo El Husseiny, Managing Partner
Series D+
£22.0M

Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.

"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
— Billy Boyle, Co-founder and CEO
Series B
£16.0M

The funding round was backed by institutional investors including Eurobank and iGrow Venture Capital, alongside a crowd-funding campaign.

"It has been an exceptional 12 months for Plum, and this new round of funding is testament to the hard work of the team and the value we’re providing for customers across Europe. The need for a smart app that helps people grow their money for life has never been stronger, and we’re already delivering this to millions of people."
— Victor Trokoudes, Founder and CEO